Retinal gene therapy based on adeno-associated viral (AAV) vectors is safe and efficient in humans. The low intrinsic DNA transfer capacity of AAV has been expanded by dual vectors where a large expression cassette is split in two halves independently packaged in two AAV vectors. Dual AAV transduction efficiency, however, is greatly reduced compared to that obtained with a single vector. As AAV intracellular trafficking and processing are negatively affected by phosphorylation, this study set to identify kinase inhibitors that can increase dual AAV vector transduction. By high-throughput screening of a kinase inhibitors library, three compounds were identified that increase AAV transduction in vitro, one of which has a higher effect on dual than on single AAV vectors. Importantly, the transduction enhancement is exerted on various AAV serotypes and is not transgene dependent. As kinase inhibitors are promiscuous, siRNA-mediated silencing of targeted kinases was performed, and AURKA and B, PLK1, and PTK2 were among those involved in the increase of AAV transduction levels. The study shows that kinase inhibitor administration reduces AAV serotype 2 (AAV2) capsid phosphorylation and increases the activity of DNA-repair pathways involved in AAV DNA processing. Importantly, the kinase inhibitor PF-00562271 improves dual AAV8 transduction in photoreceptors following sub-retinal delivery in mice. The study identifies kinase inhibitors that increase dual and single AAV transduction by modulating AAV entry and post-entry steps.
Get full access to this article
View all access options for this article.
References
1.
SohockiMM, DaigerSP, BowneSJ, et al.Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat, 2001; 17:42–51.
2.
BergerW, Kloeckener-GruissemB, NeidhardtJ. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res, 2010; 29:335–375.
3.
BainbridgeJW, SmithAJ, BarkerSS, et al.Effect of gene therapy on visual function in Leber's congenital amaurosis. New Engl J Med, 2008; 358:2231–2239.
4.
CideciyanAV, HauswirthWW, AlemanTS, et al.Vision 1 year after gene therapy for Leber's congenital amaurosis. New Engl J Med, 2009; 361:725–727.
5.
MaguireAM, SimonelliF, PierceEA, et al.Safety and efficacy of gene transfer for Leber's congenital amaurosis. New Engl J Med, 2008; 358:2240–2248.
6.
MaguireAM, HighKA, AuricchioA, et al.Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a Phase 1 dose-escalation trial. Lancet, 2009; 374:1597–1605.
7.
SimonelliF, MaguireAM, TestaF, et al.Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther, 2010; 18:643–650.
8.
TestaF, MaguireAM, RossiS, et al.Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology, 2013; 120:1283–1291.
NatkunarajahM, TrittibachP, McIntoshJ, et al.Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther, 2008; 15:463–467.
14.
BoyeSE, AlexanderJJ, BoyeSL, et al.The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther, 2012; 23:1101–1115.
15.
VandenbergheLH, BellP, MaguireAM, et al.AAV9 targets cone photoreceptors in the nonhuman primate retina. PloS One, 2013; 8:e53463.
16.
LaiY, YueY, DuanD. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther, 2010; 18:75–79.
17.
HermonatPL, QuirkJG, BishopBM, et al.The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors. FEBS Lett, 1997; 407:78–84.
18.
DongB, NakaiH, XiaoW. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther, 2010; 18:87–92.
19.
WuZ, YangH, ColosiP. Effect of genome size on AAV vector packaging. Mol Ther, 2010; 18:80–86.
20.
AllikmetsR. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet, 1997; 17:122.
21.
MillanJM, AllerE, JaijoT, et al.An update on the genetics of usher syndrome. J Ophthalmol, 2011; 2011:417217.
22.
YanZ, ZhangY, DuanD, et al.Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A, 2000; 97:6716–6721.
23.
DuanD, YueY, EngelhardtJF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther, 2001; 4:383–391.
24.
GhoshA, DuanD. Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev, 2007; 24:165–177.
25.
GhoshA, YueY, LaiY, et al.A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther, 2008; 16:124–130.
26.
TrapaniI, ColellaP, SommellaA, et al.Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med, 2014; 6:194–211.
27.
ReichSJ, AuricchioA, HildingerM, et al.Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther, 2003; 14:37–44.
DuanD, YueY, YanZ, et al.Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest, 2000; 105:1573–1587.
30.
JenningsK, MiyamaeT, TraisterR, et al.Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther, 2005; 11:600–607.
31.
LopesVS, BoyeSE, LouieCM, et al.Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther, 2013; 20:824–833.
32.
NicolsonSC, LiC, HirschML, et al.Identification and validation of small molecules that enhance recombinant adeno-associated virus transduction following high-throughput screens. J Virol, 2016; 90:7019–7031.
33.
ZhongL, ZhaoW, WuJ, et al.A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther, 2007; 15:1323–1330.
34.
ZhongL, LiB, JayandharanG, et al.Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology, 2008; 381:194–202.
35.
Petrs-SilvaH, DinculescuA, LiQ, et al.High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther, 2009; 17:463–471.
36.
AslanidiGV, RiversAE, OrtizL, et al.Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?. PloS One, 2013; 8:e59142.
37.
AuricchioA, HildingerM, O'ConnorE, et al.Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther, 2001; 12:71–76.
38.
DoriaM, FerraraA, AuricchioA. AAV2/8 vectors purified from culture medium with a simple and rapid protocol transduce murine liver, muscle, and retina efficiently. Hum Gene Ther Methods, 2013; 24:392–398.
39.
DrittantiL, RivetC, ManceauP, et al.High throughput production, screening and analysis of adeno-associated viral vectors. Gene Ther, 2000; 7:924–929.
40.
MukakaMM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J, 2012; 24:69–71.
41.
CastoriaG, GiovannelliP, LombardiM, et al.Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene, 2012; 31:4868–4877.
42.
LiangFQ, AnandV, MaguireAM, et al.Intraocular delivery of recombinant virus. Methods Mol Med, 2001; 47:125–139.
43.
BenjaminiY and HochbergY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol, 1995; 57:289–300.
44.
KalaitzisAA, LawrenceND. A simple approach to ranking differentially expressed gene expression time courses through Gaussian process regression. BMC Bioinformatics, 2011; 12:180.
45.
GaoG, VandenbergheLH, AlviraMR, et al.Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004; 78:6381–6388.
46.
AsokanA, HamraJB, GovindasamyL, et al.Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol, 2006; 80:8961–8969.
47.
ChoiVW, McCartyDM, SamulskiRJ. Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol, 2006; 80:10346–10356.
48.
RoseJA, MaizelJVJr, InmanJK, et al.Structural proteins of adenovirus-associated viruses. J Virol, 1971; 8:766–770.
49.
ColellaP, AuricchioA. Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients. Hum Gene Ther, 2012; 23:796–807.
50.
NonnenmacherM, WeberT. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther, 2012; 19:649–658.
51.
LiZ, LiJ, KongY, et al.Plk1 Phosphorylation of Mre11 antagonizes the DNA damage response. Cancer Res, 2017; 77:3169–3180.
52.
BenadaJ, BurdovaK, LidakT, et al.Polo-like kinase 1 inhibits DNA damage response during mitosis. Cell Cycle, 2015; 14:219–231.
53.
ManoM, IppodrinoR, ZentilinL, et al.Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction. Proc Natl Acad Sci U S A, 2015; 112:11276–11281.
54.
RobertsWG, UngE, WhalenP, et al.Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008; 68:1935–1944.
55.
JaniJP, ArcariJ, BernardoV, et al.PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther, 2010; 9:883–894.
56.
SteegmaierM, HoffmannM, BaumA, et al.BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol, 2007; 17:316–322.
57.
HeinrichMC, GriffithD, McKinleyA, et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res, 2012; 18:4375–4384.
58.
WernigG, KharasMG, OkabeR, et al.Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell, 2008; 13:311–320.
59.
AndersonK, LaiZ, McDonaldOB, et al.Biochemical characterization of GSK1070916, a potent and selective inhibitor of aurora B and aurora C kinases with an extremely long residence time. Biochem J, 2009; 420:259–265.
60.
BraselmannS, TaylorV, ZhaoH, et al.R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther, 2006; 319:998–1008.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
